Generic name
Lenvatinib mesylate: adverse event reports filed with FDA
5,719 reports list it as a suspect or interacting product, 2018–2026.
- 5,719
- reports as suspect product
- 0% of all reports · about 738 a year
- 295
- reports, 12 months to June 2026
- 1,078 in the 12 months before
- 73.7%
- marked serious by the reporter
- 57.4% across all reports
- 12.3%
- record death among outcomes, as reported
- 702 reports · not verified by FDA
5,719 adverse event reports received by FDA list lenvatinib mesylate, a generic name as a suspect or interacting product, from October 2018 to June 2026. A further 377 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 295 reports listed it, down 73% from 1,078 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 738 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are malignant neoplasm progression (17.9%), hypertension (17.3%) and fatigue (11.7%). A report can list several reactions, so shares add to more than 100%; 815 different terms appear across these reports. Malignant neoplasm progression is recorded in 17.9% of these reports, against 0.5% of all reports in the database.
73.7% of the reports are marked serious by the reporter; 12.3% record death among the outcomes and 34.9% record hospitalisation, as reported. 55.5% of the reports came from physicians, and the largest patient age group is 65 to 74 (25.9%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Lenvatinib mesylate reports recording the termall reports in the database
- Malignant neoplasm progression17.9%1,026
- Hypertensionhigh blood pressure17.3%988
- Fatiguetiredness11.7%671
- Diarrhoealoose or frequent stools11.3%649
- Hypothyroidismunderactive thyroid9%513
- Product use issuea problem in how the product was used9%512
- Malaisegeneral feeling of being unwell8%456
- Decreased appetitereduced appetite7.7%440
- Pyrexiafever6.1%348
- Platelet count decreasedlow platelet count6%344
- Proteinuriaprotein in the urine6%343
- Nauseafeeling sick5.9%338
- Blood pressure increaseda raised blood pressure reading5.8%331
- Rashskin rash5.3%305
- Arthralgiajoint pain4.7%271
- Renal impairmentreduced kidney function4.5%260
- Weight decreasedweight loss4.3%248
- Dysphoniaa hoarse voice4.3%245
- Stomatitissore mouth4%231
- Headachehead pain3.6%205
- Vomitingbeing sick3.4%192
- Astheniaweakness or lack of energy3.1%177
- Drug ineffectivethe medicine did not work as expected2.7%152
- Hepatic function abnormal2.6%148
- Deaththe patient died; cause not stated by this term2.4%138
- Abdominal painstomach or belly pain2.4%136
- Thrombocytopenialow platelets2.3%132
- Constipationconstipation2.3%131
- Immune-mediated hypothyroidism2.3%131
Top 30 of 815 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 40.1% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Uterine cancer | 1,608 | 28.1% |
| Endometrial cancer | 1,489 | 26% |
| Renal cell carcinoma | 506 | 8.8% |
| Renal cell carcinoma stage iv | 413 | 7.2% |
| Renal cancer | 231 | 4% |
| Endometrial adenocarcinoma | 117 | 2% |
The indication field is filled in by the reporter and is often blank; shares are of all 5,719 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Lenvatinib mesylate reports |
|---|---|---|
| Keytruda | 5,009 | 87.6% |
| Pembrolizumab | 511 | 8.9% |
| Amlodipine besylate | 185 | 3.2% |
| Eliquis | 124 | 2.2% |
| Ergocalciferol | 113 | 2% |
| Amlodipine | 101 | 1.8% |
| Levothyroxine | 90 | 1.6% |
| Levothyroxine sodium | 90 | 1.6% |
| Aspirin | 66 | 1.2% |
| Rosuvastatin calcium | 65 | 1.1% |
Other products listed in reports where Lenvatinib mesylate is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Lenvatinib mesylate | All reports |
|---|---|---|
| Reports as suspect product | 5,719 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 295 | 1,332,454 |
| Marked serious | 73.7% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 123 | 91 |
| Hospitalisation recorded, per 1,000 reports | 349 | 213 |
| Consumer-filed share | 31.9% | 45.8% |
| Top term, share of reports | Malignant neoplasm progression 17.9% | 0.5% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Lenvatinib mesylate reports
How many adverse event reports has FDA received for Lenvatinib mesylate?
5,719 reports list Lenvatinib mesylate as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 295 of them arrived in the latest 12 months. Another 377 list it only as a concomitant medication.
What reactions are recorded in Lenvatinib mesylate reports?
malignant neoplasm progression (17.9%), hypertension (17.3%), fatigue (11.7%), diarrhoea (11.3%) and hypothyroidism (9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Lenvatinib mesylate was responsible.
How serious are the reports?
73.7% are marked serious by the reporter. Among the outcomes recorded, 12.3% of reports include death and 34.9% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (55.5%), consumer or non-health professional (31.9%) and other health professional (9.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Lenvatinib mesylate rising?
295 reports in the 12 months to June 2026, down 73% from 1,078 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Lenvatinib mesylate was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Lenvatinib mesylate?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Lenvatinib mesylate as a suspect or interacting product; reports listing it only as a concomitant medication (377) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.